24/7 Market News Snapshot 22 October, 2024 – Indaptus Therapeutics, Inc. Common Stock (NASDAQ:INDP)

October 22, 2024

DENVER, Colo., 22 October, 2024 (247marketnews.com) – (NASDAQ:INDP) are discussed in this article.
Indaptus Therapeutics, Inc. is experiencing significant momentum in its stock performance, currently trading at $2.022, reflecting an impressive gain of 37.55% from yesterday’s closing price of $1.47. With a robust trading volume of 585.32K shares exchanged, the surge highlights a growing investor interest and confidence in the company’s future prospects.

At the same time, Indaptus is making strides in cancer therapy development through a recently announced clinical supply agreement with BeiGene. This collaboration marks a pivotal achievement for both companies as they prepare to embark on a groundbreaking clinical trial that will evaluate the combined efficacy of BeiGene’s checkpoint inhibitor, tislelizumab, and Indaptus’ innovative immune stimulator, Decoy20. Scheduled to begin in 2025, the trial aims to enhance treatment outcomes for patients with resistant forms of cancer.

Decoy20 has shown promising results in preclinical studies, achieving tumor eradication rates of up to 100% when administered alongside PD-1 inhibitors. This success is attributed to Indaptus’ novel “Pulse-Prime” approach, which is designed to amplify the immune system’s response while minimizing adverse effects. This technique aims not only to engage the innate immune system but also to develop a lasting anti-tumor memory, crucial for the effectiveness of cancer treatments.

CEO Jeffrey Meckler emphasized the potential impact of the partnership on treatment efficacy, expressing optimism about improving patient outcomes for those facing challenging cancers. The collaboration aims to leverage BeiGene’s advanced PD-1 inhibitor and technical expertise to expedite the initiation of this promising trial.

As Indaptus Therapeutics continues to push the boundaries of immunotherapy, it remains committed to delivering innovative solutions aimed at transforming cancer treatment. Further details about this endeavor and other developments will be discussed in an upcoming conference call on October 22, 2024.

Related news for (INDP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.